News Center

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

Jan 13, 2020 | News Press Releases
Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties. SAN DIEGO, USA and BEIJING, China,...

A Phase 1 Study of ARX788, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Metastatic HER2-Positive Breast Cancer

Dec 11, 2019 | News Publications
San Antonio Breast Cancer Symposium 2019 - ARX788 SABCS poster...

Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugates

Oct 22, 2019 | News Press Releases
SAN DIEGO and SHANGHAI, October 22, 2019 /PRNewswire/ -- Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed...

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

Jul 16, 2019 | News
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin...

Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

Mar 6, 2019 | News Press Releases
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics...